-
Dr.Guohong Han: Combining Targeted Therapy to Reduce Postoperative Liver Cancer Recurrence and Prolong Survival in Cirrhotic Patients with Anticoagulation
Hepatology Digest: Liver cancer immunotherapy has been a major focus of this year’s conference, particularly the research presented on June 23rd regarding adjuvant targeted immunotherapy for high-risk liver cancer recurrence following…
-
Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections
Currently, there is limited research on the natural history of disease in patients with chronic hepatitis B in the “gray zone,” and there is still debate about the necessity of…
-
Dr. Jun Li’s Team: ETS2 as a Potential New Target for the Diagnosis and Treatment of HBV-ACLF, Alleviating Liver Failure Progression by Suppressing Macrophage Immune Inflammatory Response
Research Introduction Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a complex clinical syndrome characterized by acute decompensation of liver function on the basis of chronic hepatitis B, often accompanied…
-
Dr. George-Lau: Advances and Reflections on Hepatitis B and Hepatitis D New Therapies
Hepatology Digest: Can you talk about the research developments at this conference that you find particularly noteworthy? Dr. George-Lau: There are many small molecule drugs under investigation for hepatitis B, such…
-
Dr. Zhang Huilai: Groundbreaking Research in Hodgkin Lymphoma
01 CD47/PD-L1 Bispecific Antibody (IBI322) Treatment for PD-1 or PD-L1 Resistant Classical Hodgkin Lymphoma (cHL): Efficacy and Safety in Phase I Study Abstract Number: S216 Presenting Expert: Yu Jingwei, Tianjin…
-
Dr. Zhou Daobin: Exploring the Application of Sequential High-Dose Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma Patients Without Chemotherapy
Background High-dose methotrexate (MTX) is widely used in frontline treatment for primary central nervous system lymphoma (PCNSL). Clinical data have shown that the new generation immunomodulator pomalidomide and Bruton kinase…
-
ABC7|Dr.Javier Cortes:Treatment directions and prospects for HER2+ advanced breast cancer treatment
HER2+ (HER2-positive) breast cancer is a type of breast cancer subtype with strong aggressiveness and poor prognosis. With the approval of more new targeted drugs for clinical application, the prognosis of HER2+ breast cancer patients continues to improve. In the absence of previous anti-HER2 targeted therapy, patients with HER2+ have a higher risk of recurrence.…
-
ABC7 | Dr.Ginny Mason:Working together to help breast cancer patients recover
The decisions faced by cancer patients are often many and complex. At present, the doctor-patient co-decision model is widely used in cancer patients. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7) “Patient advocacy session: Complexities of shared decision making “featured experts discussing complexities of shared decision making among patients.Oncology Frontier invited Dr.Ginny…
Connecting Medical Expertise through Media